Kathryn Lees

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer

Gianmarco Leone, Francesco Orlando, Peter Dutey‐Magni, Osvaldas Vainauskas et autres

gb, it (code pays fourni par la source)

Outcome of radical chemoradiation in node-positive bladder cancer: The Kent experience

S. Bhusal, Rakesh Raman, A. Edwards, Charalampos Thomas et autres

gb (code pays fourni par la source)

1731: Rad-led Prehabilitation Clinic increases number of successful prostate radiotherapy CTplanning scans

Emma Simpson, Kathryn Lees, Sara Hodgkinson, Claire Johnson et autres

Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)

Chris Parker, René Horsleben Petersen, Adrian Cook, Noel W. Clarke et autres

gb, dk, ca, ie, us (code pays fourni par la source)

Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes

Sarah Benafif, Ann-Britt Jones, Susan Merson, Reshma Rageevakumar et autres

gb, dk (code pays fourni par la source)

Evaluating the impact of the metastatic spinal cord compression coordinator in a regional cancer network: a prospective, non-randomized pilot study

Rubyyat-A Hakim, Joao R Galante, Huma Zahid, Mariya Karova et autres

gb (code pays fourni par la source)

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory, Christy Ralph et autres

gb (code pays fourni par la source)

A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma

Simon J. Crabb, Syed A. Hussain, Eileen Soulis, Samantha Hinsley et autres

gb (code pays fourni par la source)

Prediction of disability-free survival in healthy older people

Franz–Josef Neumann, Lê Thị Phương Thảo, Anne M. Murray, Emily Callander et autres

au, de, us (code pays fourni par la source)

A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.

Simon J. Crabb, Syed A. Hussain, Eileen Soulis, Samantha Hinsley et autres

gb (code pays fourni par la source)

Use of Novel Imaging for Patient Selection for Stereotactic Ablative Radiotherapy (SABR) in Oligometastatic Prostate Cancer (PCa): Does the PET Tracer Make a Difference?

Joao R Galante, Sola Adeleke, M Wong, Audrey Choy et autres

gb (code pays fourni par la source)

414P Does adjuvant chemotherapy compared to surveillance improve recurrence free and overall survival in stage 3 rectal cancer patients?

Sola Adeleke, Suzanne George, Joao R Galante, Mariya Karova et autres

gb (code pays fourni par la source)